CellaVision ABCVLLY +12.06%69 Gross Margin % is 68.50% as of Mar. 2026, which is 1% below its 10-year median of 68.97. GuruFocus rates CVLLY with a GF Score™ of 69/100 and a GF Value™ of $12.48 (Significantly Undervalued). The stock has 1 warning sign investors should review. Among 805 Medical Devices & Instruments companies, CellaVision AB ranks better than 76.4% on this metric.
The historical rank and industry rank for CellaVision AB's Gross Margin % or its related term are showing as below:
CVLLY'
s Gross Margin % Range Over the Past 10 Years
Min: 66.4 Med: 68.97 Max: 74.25
Current: 67.98
During the past 13 years, the highestGross Margin % of CellaVision AB was 74.25%. The lowest was 66.40%. And the median was 68.97%.
CVLLY's Gross Margin % is ranked better than 76.4% of 805
companies
in the Medical Devices & Instruments industry
Industry Median: 52.07
vs CVLLY: 67.98
CellaVision AB had a gross margin of 68.50% for the quarter that ended in Mar. 2026 => Durable competitive advantage
The 5-Year average Growth Rate of Gross Margin for CellaVision AB was 0.20% per year.
CellaVision AB (OTCPK:CVLLY) Gross Margin % Explanation
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
CellaVision AB had a gross margin of 68.50% for the quarter that ended in Mar. 2026 => Durable competitive advantage
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
CellaVision AB Gross Margin % Related Terms
CellaVision AB Gross Margin % Historical Data
* Premium members only.
The historical data trend for CellaVision AB's Gross Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, CellaVision AB's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
CellaVision AB Gross Margin % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, CellaVision AB's Gross Margin % distribution charts can be found below:
* The bar in red indicates where CellaVision AB's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
CellaVision AB (CVLLY) has a Gross Margin % of 68.50% as of Mar. 2026. Gross margin is the ratio of total gross profit to net sales. View historical data on CellaVision AB and its competitors. This is near median its historical median of 68.97. Over the past decade, CellaVision AB's Gross Margin % has ranged from 66.40 to 74.25. According to the industry distribution chart, CellaVision AB ranks #190 out of 805 companies in the Medical Devices & Instruments industry, placing it in the top 23.6%.
Is CellaVision AB's Gross Margin % too high?
CellaVision AB's current Gross Margin % of 68.50% is near median its 10-year median of 68.97. Over the past 10 years, this metric has ranged from a low of 66.40 to a high of 74.25. The Medical Devices & Instruments industry median Gross Margin % is 52.07. CellaVision AB's value of 68.50% is 31.6% above this industry median. Based on the distribution chart, CellaVision AB ranks #190 out of 805 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, CellaVision AB has a GF Score™ of 69/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does CellaVision AB's Gross Margin % compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, CellaVision AB ranks #190 out of 805 companies for Gross Margin %. This places CellaVision AB in the top 24% of its industry — outperforming the majority of peers. The industry median Gross Margin % is 52.07. CellaVision AB's value of 68.50% is 31.6% above this benchmark. Historically, CellaVision AB's own Gross Margin % has ranged from 66.40 to 74.25 over the past decade. While the company's 10-year median is 68.97 vs. the industry median of 52.07, CellaVision AB has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Medical Devices & Instruments company?
The median Gross Margin % among Medical Devices & Instruments companies is 52.07, based on 805 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. CellaVision AB's current Gross Margin % of 68.50% is 31.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on CellaVision AB and its competitors. For the Medical Devices & Instruments industry, the median Gross Margin % is 52.07 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. CellaVision AB's current Gross Margin % is 68.50%, which is near median its own 10-year median of 68.97. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CellaVision AB stock overvalued right now?
Based on GuruFocus' analysis, CellaVision AB (CVLLY) is currently considered Significantly Undervalued. The stock's GF Value™ is $12.48, compared to a current price of $7.06 — trading 43.4% below its estimated fair value. The current Gross Margin % is 68.50%, which is near median its 10-year median of 68.97 and 31.6% above the Medical Devices & Instruments industry median of 52.07. CellaVision AB's overall GF Score™ is 69/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For CellaVision AB (CVLLY), the current Gross Margin % is 68.50% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is CellaVision AB (CVLLY) Overvalued in 2026?
Based on GuruFocus' analysis, CellaVision AB stock appears to be undervalued.
The current stock price of $7.06 is trading 43.4% below its estimated GF Value™ of $12.48.
GuruFocus considers CellaVision AB to be Significantly Undervalued.
Key valuation signals for CVLLY:
Gross Margin %: 68.50% (near median its 10-year median of 68.97)
GF Value™: $12.48 vs. price of $7.06 (43.4% below fair value)
Industry Position: 31.6% above the Medical Devices & Instruments median (#190 of 805)
No single metric tells the full story. See the CVLLY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
CellaVision AB is engaged in developing and selling instruments, software, and reagents for blood and body fluid analysis. The company automates parts of the sample preparation process and replaces manual microscopes with instruments based on digital image analysis technology and artificial intelligence. The solutions contribute to more effective workflows and higher quality in laboratory medicine. The product offer consists of products and solutions for standardized laboratory diagnostics and improved performance for cellular image processing and systems for digital microscopy in hematology, consisting of reagents, instruments, and supplementary software and peripheral equipment.
69GF Score
Get the complete analysis for CVLLY
Gross Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CVLLY has been successfully added to your 
